Searched for: subject%3A%22Fibrinolysis%22
(1 - 20 of 115)

Pages

document
Hellgren, M. (author), Conard, J. (author), Norris, L. (author), Kluft, C. (author), TNO Kwaliteit van Leven (author)
Objective: To study cardiovascular risk markers in women taking estradiol/trimegestone or estradiol/dydrogesterone. Design: Multicenter, randomized, prospective, double-blind study of 184 healthy post-menopausal women randomized to 6 cycles of either estradiol (2 mg) + trimegestone (0.5 mg) (T-group) or estradiol (2 mg) + dydrogesterone (10 mg) ...
article 2009
document
Rijken, D.C. (author), Hoegee-de Nobel, E. (author), Jie, A.F.H. (author), Atsma, D.E. (author), Schalij, M.J. (author), Nieuwenhuizen, W. (author), TNO Kwaliteit van Leven (author)
Background: The development of global tests for the fibrinolytic capacity in blood is hampered by the low base-line fibrinolytic activity in blood, by the involvement of both plasmatic components and blood cells in the fibrinolytic system and by the loss of fibrinolytic activity as a result of the action of plasminogen activator inhibitor-1 (PAI...
article 2008
document
Hemelaar, M. (author), van der Mooren, M.J. (author), Rad, M. (author), Kluft, C. (author), Kenemans, P. (author), TNO Kwaliteit van Leven (author)
Objective: To review the effects of non-oral administration of postmenopausal hormone therapy (HT) on risk markers for atherosclerotic and venous thromboembolic disease.Non-oral postmenopausal HT appears not to increase venous thromboembolic risk, whereas the effect on coronary heart disease risk is less clear. Design: Systematic review of...
article 2008
document
Norris, L.A. (author), Brosnan, J. (author), Bonnar, J. (author), Conard, J. (author), Kluft, C. (author), Hellgren, M. (author), TNO Kwaliteit van Leven (author)
Epidemiological studies have shown that hormone therapy (HT) increases the risk of venous thromboembolism in post menopausal women. The mechanism of this increased risk is unknown; however, activation of the haemostatic system is known to contribute to the pathogenesis of venous thromboembolism. In post-menopausal women the estrogen /progestogen...
article 2008
document
Rad, M. (author), Kluft, C. (author), Ménard, J. (author), Burggraaf, J. (author), de Kam, M.L. (author), Meijer, P. (author), Sivin, I. (author), Sitruk-Ware, R.L. (author), TNO Kwaliteit van Leven (author)
Objective: This study aimed to compare the effects on hemostasis variables of a contraceptive vaginal ring with those of an oral contraceptive. Study design: Twenty-three and 22 healthy premenopausal women were randomized to the contraceptive vaginal ring (150 μg Nestorone and 15 μg ethinyl estradiol) or Stediril 30 during 3 cycles. Analysis of...
article 2006
document
Bertina, R.M. (author), van Tilburg, N.H. (author), Haverkate, F. (author), Bouma, B.N. (author), von dem Borne, P.A.K. (author), Meijers, J.C.M. (author), Campbell, W. (author), Eaton, D. (author), Hendriks, D.F. (author), Willemse, J.L. (author), TNO Kwaliteit van Leven (author)
CAS: blood clotting factor 11, 9013-55-2; thrombin, 9002-04-4; tissue plasminogen activator, 105913-11-9; protein C, 60202-16-6; Carboxypeptidase U, 3.4.17.20; Protein C; Tissue Plasminogen Activator, 3.4.21.68
article 2006
document
Kluft, C. (author), Endrikat, J. (author), Mulder, S.M. (author), Gerlinger, C. (author), Heithecker, R. (author), TNO Kwaliteit van Leven (author)
Purpose: In this open-label, randomized study, we assessed the effects on hemostasis of two combined oral contraceptives containing drospirenone (DRSP) as progestogen component. Methods: Three milligrams of DRSP, a progestogen with antimineralocorticoid activity, was combined with either 30 or 20 μg ethinyl estradiol (EE) (DRSP/30EE; DRSP/20EE)...
article 2006
document
Vogelvang, T.E. (author), Mijatovic, V. (author), Kenemans, P. (author), Emeis, J.J. (author), Heijst, J.A. (author), van der Mooren, M.J. (author), TNO Preventie en Gezondheid (author)
Objective: To investigate the short-term effects of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis. Study design: In a multicenter, 14-week, randomized, placebo-controlled, double-blind, dose-ranging study, healthy postmenopausal women received daily placebo (n = 22), HMR 3339 2.5 mg (n = 25),...
article 2005
document
Guimarães, A.H.C. (author), van Tilburg, N.H. (author), Vos, H.L. (author), Bertina, R.M. (author), Rijken, D.C. (author)
Thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels exhibit a large interindividual variability in which genetic control seems to play a major role. However, recent reports have questioned the association between TAFI concentration and genotype, suggesting that variable antibody reactivity towards TAFI isoforms, particularly the...
article 2004
document
de Maat, M.P.M. (author), Jansen, M.W.J.C. (author), Hille, E.T.M. (author), Vos, H. (author), Bloemenkamp, K.W.M. (author), Buitendijk, S.E. (author), Helmerhorst, F.M. (author), Wladimiroff, J.W. (author), Bertina, R.M. (author), de Groot, C.J.M. (author), TNO Preventie en Gezondheid (author)
Recently, it has been proposed that abnormalities in coagulation and fibrinolysis contribute to the development of preeclampsia by increasing the thrombotic tendency. This hypothesis was tested in women who have had preeclampsia (cases) compared with matched controls. Polymorphisms in the thrombophilia genes {plasminogen activator inhibitor type...
article 2004
document
Rijken, D.C. (author), Barrett-Bergshoeff, M.M. (author), Jie, A.F.H. (author), Criscuoli, M. (author), Sakharov, D.V. (author), Gaubius Instituut TNO (author)
Amediplase (K2tu-PA) is a hybrid plasminogen activator, consisting of the kringle 2 domain of alteplase and the protease domain of urokinase. The objective of this study was to determine the in vitro clot penetration of amediplase in relation to its fibrin binding and to compare the properties with those of alteplase. The clot lysis activity of...
article 2004
document
Gaubius Instituut TNO (author), Walker, J.B. (author), Hughes, B. (author), James, I. (author), Haddock, P. (author), Kluft, C. (author), Bajzar, L. (author)
Two competitive inhibitors of TAFIa (activated thrombin-activable fibrinolysis inhibitor), 2-guanidinoethyl-mercaptosuccinic acid and potato tuber carboxypeptidase inhibitor, variably affect fibrinolysis of clotted human plasma. Depending on their concentration, the inhibitors shortened, prolonged, or had no effect on lysis in vitro. The...
article 2003
document
Kuenen, B.C. (author), Levi, M. (author), Meijers, J.C.M. (author), Kakkar, A.K. (author), van Hinsbergh, V.W.M. (author), Kostense, P.J. (author), Pinedo, H.M. (author), Hoekman, K. (author), Gaubius Instituut TNO (author)
Objective - The angiogenesis inhibitor SU5416 is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor-1 and -2. VEGF may be involved in hemostasis by altering the hemostatic properties of endothelial cells. We analyzed the effects of SU5416 on the coagulation cascade and the vessel wall in patients with advanced cancer....
article 2002
document
Reijnen, M.M.P.J. (author), Holmdahl, L. (author), Kooistra, T. (author), Falk, P. (author), Hendriks, T. (author), van Goor, H. (author), TNO Kwaliteit van Leven (author)
Background: This study assessed the peritoneal fibrinolytic response during the first week after colonic surgery in rats with and without bacterial peritonitis, and possible modulation of the response by two hyaluronan-based antiadhesive agents. Methods: A colonic anastomosis was constructed in 90 male Wistar rats. Peritonitis was induced in...
article 2002
document
Goedde, M.F. (author), Grimbergen, J.M. (author), Toet, K.H. (author), Sitter, T. (author), Quax, P.H. (author), Kooistra, T. (author), Gaubius Instituut TNO (author)
Background. The mesothelium has an important role in maintaining an adequate fibrinolytic capacity in the peritoneal cavity and thus in preventing the formation of fibrinous peritoneal adhesions by secreting the fibrinolytic enzyme tissue-type plasminogen activator (t-PA). The fibrinolytic activity of human mesothelial cells (HMCs) is...
article 2001
document
Giltay, E.J. (author), Gooren, L.J.G. (author), Emeis, J.J. (author), Kooistra, T. (author), Stehouwer, C.D.A. (author), TNO Preventie en Gezondheid (author)
Oral estrogen administration decreases plasma levels of tissue-type plasminogen activator (tPA), which may be explained by a decrease in endothelial tPA synthesis, an increase in its hepatic clearance, or both. In the present study, we determined (1) differences between oral (ie, via the liver) ethinyl estradiol and transdermal (ie, systemic)...
article 2000
document
Sakharov, D.V. (author), Hekkenberg, R.T. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
High-frequency ultrasound has been shown to accelerate enzymatic fibrinolysis. One of the supposed mechanisms of this effect is the enhancement of mass transport by acoustic streaming, i.e., ultrasound-induced macroscopic flow around the clot. In this study, which is aimed at further elucidating the mechanisms of the acceleration of fibrinolysis...
article 2000
document
TNO Preventie en Gezondheid (author), Meijers, J.C.M. (author), Oudijk, E.J.D. (author), Mosnier, L.O. (author), Bos, R. (author), Bouma, B.N. (author), Nieuwenhuis, H.K. (author), Fijnheer, R. (author)
Acute promyelocytic leukaemia (APL) is a disease that is distinguished from other leukaemias by the high potential for early haemorrhagic death. Several processes are involved, such as disseminated intravascular coagulation and hyperfibrinolysis. Recently, TAFI (thrombin-activatable fibrinolysis inhibitor) was identified as a link between...
article 2000
document
Gaubius Instituut TNO (author), Braat, E.A.M. (author), Jie, A.F.H. (author), Ronday, H.K. (author), Beekman, B. (author), Rijken, D.C. (author)
Background - Excessive fibrin deposition within the inflamed joints of rheumatoid arthritis (RA) patients suggests that local fibrinolysis is inefficient, which seems to be in contrast with the observed increased levels of urokinase type plasminogen activator (u-PA). Thrombin-mediated inactivation of single chain u-PA (scu-PA) into an inactive...
article 2000
document
Lansink, M. (author), Jong, M. (author), Bijsterbosch, M. (author), Bekkers, M. (author), Toet, K. (author), Havekes, L. (author), Emeis, J. (author), Kooistra, T. (author), Gaubius instituut TNO (author)
Several clinical studies have demonstrated an inverse relationship between circulating levels of estrogen and tissue-type plasminogen activator (t-PA). The present study was designed to test the hypothesis that estrogen lower plasma levels of t-PA by increasing its clearance from the bloodstream. 17α-Ethinyl estradiol (EE) treatment resulted in...
article 1999
Searched for: subject%3A%22Fibrinolysis%22
(1 - 20 of 115)

Pages